<DOC>
	<DOCNO>NCT02692339</DOCNO>
	<brief_summary>Multicentre , prospective , observational , open-label , single arm , post-marketing study intend record Lenalidomide/Dexamethasone treatment data patient relapsed/refractory Multiple Myeloma ( rrMM ) treat setting define standard clinical practice approve Summary Product Characteristics ( SmPC ) .</brief_summary>
	<brief_title>Safety Study Lenalidomide/Dexamethasone Treat Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This study aim ass real-life safety Lenalidomide/Dexamethasone ( Len/Dex ) patient ( Relapsed Refractory Multiple Myeloma ( rrMM ) , evaluation adverse event special interest ( infection , gastrointestinal event , thrombocytopenia , neutropenia , febrile neutropenia , thromboembolism ) . In addition , due scarce information regard impact frailty Len/Dex treatment rrMM , study prospectively assess Len/Dex safety effectiveness patient frailty group . The follow study assessment perform : - Recruitment : patient recruit within 15 day start Len/Dex ( day 1 day 15 ) . In case patient recruit day Len/Dex start ( day 1 ) , baseline information respective day collect retrospectively . - Treatment period : period , follow assessment carry : - Every 30 day ( ± 5 day ) adverse event , change concomitant medication change Len/Dex dose . - Every 90 day ( ± 15 day ) remain information collect treatment period - Assessment end Len/Dex treatment ( 5 day end treatment ) . Follow-up assessment 90 day ( ± 15 day ) end Len/Dex treatment . No visit predefined study . Study data plan collected patient go study site clinical routine visit . No assessment impose purpose study . If patient go clinical routine visit date time interval predict , information collect . Information collect context routine clinical practice . The patient follow end Len/Dex treatment , death discontinuation reason maximum period 36 month , Patients within treatment maximum period stop follow study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients age 18 year higher . 2 . Patients voluntarily give write informed consent participate study data retrieve purpose study 3 . Patients diagnose 1st 2nd relapsed refractory multiple myeloma indicate 2nd 3rd line Len/Dex treatment , accord SmPC ( patient receive least one prior therapy ) 1 . Pregnant lactate patient 2 . Female patient childbearing potential unable unwilling use effective contraceptive method , state summary product characteristic : Implant . Levonorgestrelreleasing intrauterine system . Medroxyprogesterone acetate depot . Tubal sterilisation . Sexual intercourse vasectomise male partner ; vasectomy must confirm two negative semen analysis . Ovulation inhibitory progesteroneonly pill ( i.e . desogestrel ) . Male patient unable follow comply require contraceptive measure state SmPC ( use condom engage sexual activity pregnant woman woman childbearing potential use effective contraception [ even man vasectomy ] , treatment 1 week dose interruption and/or cessation treatment ) 3 . Hypersensitivity active substance excipients 4 . Patients participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Observational Study</keyword>
	<keyword>Safety Len/Dex</keyword>
</DOC>